diagnosis
Pathological diagnosis should be made according to the new World Health Organization/European Organization for Research and Treatment of Cancer classification. A surgical specimen providing enough material also for fresh frozen samples is preferred over punch biopsies. Reactive lymphatic processes have to be ruled out carefully, taking into account their possible clonal nature.
staging and risk assessment
History, clinical findings, laboratory parameters, and imaging techniques (ultrasound of abdomen and major lymph node regions or computed tomography scans) are necessary to exclude extranodal manifestations or an extranodal origin therapy. Prognosis is extremely variable depending on the exact subtype, origin, and stage of the lymphoma.
treatment plan
Due to the heterogeneity and rarity of the disease, most recommendations are not on the basis of high-level evidence. Treatment requires close cooperation with a center experienced in dermatology and oncology. 
follow-up
There is no proof that close monitoring with laboratory or radiological tests influences survival. Restricted to lymphomas of a/b T-cell origin. b On the basis of recent evidence suggesting derivation from a plasmacytoid dendritic cell precursor; this condition has also been designated as early plasmacytoid dendritic cell leukemia/lymphoma. 
